vs
Side-by-side financial comparison of Hologic (HOLX) and Schneider National, Inc. (SNDR). Click either name above to swap in a different company.
Schneider National, Inc. is the larger business by last-quarter revenue ($1.4B vs $1.0B, roughly 1.3× Hologic). Hologic runs the higher net margin — 17.1% vs 1.6%, a 15.5% gap on every dollar of revenue. On growth, Schneider National, Inc. posted the faster year-over-year revenue change (4.5% vs 2.5%). Hologic produced more free cash flow last quarter ($215.2M vs $145.5M). Over the past eight quarters, Schneider National, Inc.'s revenue compounded faster (3.0% CAGR vs 1.5%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
Schneider National, Inc. is an American transportation company that provides truckload, intermodal, and logistics services. Schneider's services include regional, long-haul, expedited, dedicated, bulk, intermodal, brokerage, cross-dock logistics, pool point distribution, supply chain management, and port logistics.
HOLX vs SNDR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $1.4B |
| Net Profit | $179.1M | $22.1M |
| Gross Margin | 56.0% | — |
| Operating Margin | 22.6% | 2.6% |
| Net Margin | 17.1% | 1.6% |
| Revenue YoY | 2.5% | 4.5% |
| Net Profit YoY | -10.9% | -32.2% |
| EPS (diluted) | $0.79 | $0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $1.4B | ||
| Q3 25 | $1.0B | $1.5B | ||
| Q2 25 | $1.0B | $1.4B | ||
| Q1 25 | $1.0B | $1.4B | ||
| Q4 24 | $1.0B | $1.3B | ||
| Q3 24 | $988.0M | $1.3B | ||
| Q2 24 | $1.0B | $1.3B | ||
| Q1 24 | $1.0B | $1.3B |
| Q4 25 | $179.1M | $22.1M | ||
| Q3 25 | $187.2M | $19.4M | ||
| Q2 25 | $194.9M | $36.0M | ||
| Q1 25 | $-17.4M | $26.1M | ||
| Q4 24 | $201.0M | $32.6M | ||
| Q3 24 | $178.6M | $30.6M | ||
| Q2 24 | $194.5M | $35.3M | ||
| Q1 24 | $169.9M | $18.5M |
| Q4 25 | 56.0% | — | ||
| Q3 25 | 55.6% | — | ||
| Q2 25 | 56.3% | — | ||
| Q1 25 | 37.5% | — | ||
| Q4 24 | 56.8% | — | ||
| Q3 24 | 56.4% | — | ||
| Q2 24 | 55.4% | — | ||
| Q1 24 | 53.3% | — |
| Q4 25 | 22.6% | 2.6% | ||
| Q3 25 | 22.6% | 2.4% | ||
| Q2 25 | 24.9% | 3.9% | ||
| Q1 25 | -0.7% | 3.0% | ||
| Q4 24 | 22.5% | 3.2% | ||
| Q3 24 | 23.3% | 3.3% | ||
| Q2 24 | 24.1% | 3.9% | ||
| Q1 24 | 20.7% | 2.2% |
| Q4 25 | 17.1% | 1.6% | ||
| Q3 25 | 17.8% | 1.3% | ||
| Q2 25 | 19.0% | 2.5% | ||
| Q1 25 | -1.7% | 1.9% | ||
| Q4 24 | 19.7% | 2.4% | ||
| Q3 24 | 18.1% | 2.3% | ||
| Q2 24 | 19.2% | 2.7% | ||
| Q1 24 | 16.7% | 1.4% |
| Q4 25 | $0.79 | $0.13 | ||
| Q3 25 | $0.84 | $0.11 | ||
| Q2 25 | $0.86 | $0.20 | ||
| Q1 25 | $-0.08 | $0.15 | ||
| Q4 24 | $0.87 | $0.19 | ||
| Q3 24 | $0.75 | $0.17 | ||
| Q2 24 | $0.82 | $0.20 | ||
| Q1 24 | $0.72 | $0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $41.8M |
| Total DebtLower is stronger | $2.5B | $390.9M |
| Stockholders' EquityBook value | $5.2B | $3.0B |
| Total Assets | $9.2B | $4.8B |
| Debt / EquityLower = less leverage | 0.48× | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4B | $41.8M | ||
| Q3 25 | $2.2B | $235.7M | ||
| Q2 25 | $1.9B | $205.1M | ||
| Q1 25 | $1.6B | $154.3M | ||
| Q4 24 | $2.0B | $165.5M | ||
| Q3 24 | $2.3B | $231.6M | ||
| Q2 24 | $2.4B | $157.2M | ||
| Q1 24 | $2.2B | $124.2M |
| Q4 25 | $2.5B | $390.9M | ||
| Q3 25 | $2.5B | $509.8M | ||
| Q2 25 | $2.5B | $512.7M | ||
| Q1 25 | $2.5B | $565.8M | ||
| Q4 24 | $2.5B | $420.8M | ||
| Q3 24 | $2.5B | $124.7M | ||
| Q2 24 | $2.5B | $125.8M | ||
| Q1 24 | $2.6B | $96.6M |
| Q4 25 | $5.2B | $3.0B | ||
| Q3 25 | $5.0B | $3.0B | ||
| Q2 25 | $4.8B | $3.0B | ||
| Q1 25 | $4.6B | $3.0B | ||
| Q4 24 | $4.8B | $3.0B | ||
| Q3 24 | $5.1B | $3.0B | ||
| Q2 24 | $5.0B | $3.0B | ||
| Q1 24 | $4.8B | $2.9B |
| Q4 25 | $9.2B | $4.8B | ||
| Q3 25 | $9.0B | $5.0B | ||
| Q2 25 | $8.8B | $5.0B | ||
| Q1 25 | $8.5B | $5.0B | ||
| Q4 24 | $8.7B | $4.9B | ||
| Q3 24 | $9.2B | $4.6B | ||
| Q2 24 | $8.9B | $4.5B | ||
| Q1 24 | $8.7B | $4.6B |
| Q4 25 | 0.48× | 0.13× | ||
| Q3 25 | 0.50× | 0.17× | ||
| Q2 25 | 0.52× | 0.17× | ||
| Q1 25 | 0.55× | 0.19× | ||
| Q4 24 | 0.53× | 0.14× | ||
| Q3 24 | 0.49× | 0.04× | ||
| Q2 24 | 0.51× | 0.04× | ||
| Q1 24 | 0.53× | 0.03× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $186.0M |
| Free Cash FlowOCF − Capex | $215.2M | $145.5M |
| FCF MarginFCF / Revenue | 20.5% | 10.4% |
| Capex IntensityCapex / Revenue | 1.4% | 2.9% |
| Cash ConversionOCF / Net Profit | 1.28× | 8.42× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $285.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $229.9M | $186.0M | ||
| Q3 25 | $355.1M | $184.2M | ||
| Q2 25 | $343.3M | $175.5M | ||
| Q1 25 | $169.4M | $91.7M | ||
| Q4 24 | $189.3M | $199.5M | ||
| Q3 24 | $367.0M | $206.4M | ||
| Q2 24 | $405.8M | $182.6M | ||
| Q1 24 | $292.4M | $97.6M |
| Q4 25 | $215.2M | $145.5M | ||
| Q3 25 | $341.4M | $56.2M | ||
| Q2 25 | $330.5M | $106.4M | ||
| Q1 25 | $153.9M | $-22.7M | ||
| Q4 24 | $172.5M | $113.6M | ||
| Q3 24 | $350.6M | $98.7M | ||
| Q2 24 | $385.3M | $85.5M | ||
| Q1 24 | $279.6M | $-25.7M |
| Q4 25 | 20.5% | 10.4% | ||
| Q3 25 | 32.5% | 3.9% | ||
| Q2 25 | 32.3% | 7.5% | ||
| Q1 25 | 15.3% | -1.6% | ||
| Q4 24 | 16.9% | 8.5% | ||
| Q3 24 | 35.5% | 7.5% | ||
| Q2 24 | 38.1% | 6.5% | ||
| Q1 24 | 27.5% | -1.9% |
| Q4 25 | 1.4% | 2.9% | ||
| Q3 25 | 1.3% | 8.8% | ||
| Q2 25 | 1.3% | 4.9% | ||
| Q1 25 | 1.5% | 8.2% | ||
| Q4 24 | 1.6% | 6.4% | ||
| Q3 24 | 1.7% | 8.2% | ||
| Q2 24 | 2.0% | 7.4% | ||
| Q1 24 | 1.3% | 9.3% |
| Q4 25 | 1.28× | 8.42× | ||
| Q3 25 | 1.90× | 9.49× | ||
| Q2 25 | 1.76× | 4.88× | ||
| Q1 25 | — | 3.51× | ||
| Q4 24 | 0.94× | 6.12× | ||
| Q3 24 | 2.05× | 6.75× | ||
| Q2 24 | 2.09× | 5.17× | ||
| Q1 24 | 1.72× | 5.28× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
SNDR
| Transportation | $1.3B | 93% |
| Logistics Management | $52.3M | 4% |
| Other | $46.2M | 3% |
